Biovest to Present at Cancer Immunotherapy Conference
Business Wire “Press Releases – English “
TAMPA, Fla. & MINNEAPOLIS –(BUSINESS WIRE)– Biovest International, Inc. (OTCQB:BVTI) today announced that the Company is scheduled to present at the MD Becker Cancer Immunotherapy Conference on October 21, 2010 , at the New York Academy of Medicine in New York City .
Dr. Carlos F. Santos , Biovests Vice President, Product Development & Regulatory Affairs, will present an overview of BiovaxID, a personalized cancer vaccine for the treatment of follicular non-Hodgkins lymphoma and mantle cell lymphoma. Biovest , in collaboration with the National Cancer Institute , has completed two Phase II studies and a Phase III study for BiovaxID. Dr. Santos is scheduled to present at 3:45 p.m. (EDT) .
Hosted by MD Becker Partners and BioBusiness.TV, the Cancer Immunotherapy: A Long-Awaited Reality conference includes keynote speakers including from the Cancer Research Institute and the Fred Hutchinson Cancer Research Center , panelist and plenary sessions, company presentations including Dendreon , and intimate networking opportunities to meet the needs of all attendees. Pre-registration is required and attendance is limited; no walk-ins.
Event: MD Becker Cancer Immunotherapy: A Long-Awaited Reality Conference
When: October 21 st, 2010 at 3:45 p.m. (EDT)
Place: New York Academy of Medicine , 1216 Fifth Ave. , New York City
Pre-registration is required: http://www.mdbpartners.com/vaccine
There will be a corresponding live webcast of the conference, which can be accessed by visiting http://www.mdbpartners.com/vaccine.
To meet with Biovest at this event, please contact Douglas Calder at 813-864-2558 or email@example.com.